Magnus Financial Group
LUCD icon

Magnus Financial Group’s Lucid Diagnostics LUCD Stock Holding History

Magnus Financial Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$30.7K Sell
40,900
-14,500
-26% -$13.6K ﹤0.01% 412
2026
Q2 		$59.3K Buy
+55,400
New +$59.7K ﹤0.01% 389

Other funds holding LUCD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Perkins Capital Management
Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Magnus Financial Group's LUCD Position: Q3 2026 in Review

Magnus Financial Group reduced its Lucid Diagnostics (LUCD) stake by 26% in Q3 2026, selling an estimated $13.6K and leaving 40,900 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #412.

Magnus Financial Group first reported a position in LUCD in Q2 2026 and has held it in 2 quarters since. The position peaked at $59.3K in Q2 2026. 82 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • Magnus Financial Group held 40,900 shares of Lucid Diagnostics worth $30.7K as of Q3 2026.
  • Magnus Financial Group sold 14,500 Lucid Diagnostics shares in Q3 2026, an estimated $13.6K.
  • Lucid Diagnostics made up ﹤0.01% of Magnus Financial Group's portfolio in Q3 2026, its #412 holding.
  • Magnus Financial Group first reported a position in Lucid Diagnostics in Q2 2026 and has held it in 2 quarters since.
  • Magnus Financial Group's Lucid Diagnostics position peaked at $59.3K in Q2 2026.
  • 82 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on Magnus Financial Group's 13F filing for Q3 2026, filed 21 Oct 2026.